Sanofi Expanding Insulin Savings Program to Insured Patients

By Colin Kellaher

Sanofi is expanding its U.S. insulin savings program to include all U.S. patients who have a valid prescription, regardless of their insurance status.

Sanofi on Friday said the program will offer a 30-day supply of any of the French drugmaker's insulin for $35 starting to all U.S. patients on Jan. 1.

The company said the program, which it created in 2018 for people without health insurance, will soon be available to all Americans regardless of insurance status, including those with commercial insurance or Medicare.

Sanofi's insulin products include Admelog, Apidra, Lantus, Merilog, Soliqua and Toujeo.

Write to Colin Kellaher at colin.kellaher@wsj.com